Tango Therapeutics, Inc.

NasdaqGM TNGX

Tango Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -137.20 M

Tango Therapeutics, Inc. EBITDA is USD -137.20 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -27.80% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Tango Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -107.36 M, a -6.09% change year over year.
Tango Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -101.19 M, a -128.37% change year over year.
Tango Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -44.31 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGM: TNGX

Tango Therapeutics, Inc.

CEO	Dr. Barbara L. Weber M.D.
IPO Date	Sept. 3, 2020
Location	United States
Headquarters	100 Binney Street
Employees	140
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years